Addressing Safety Risks In mRNA Therapeutics
Source: Roche CustomBiotech
Safety of mRNA vaccines and therapeutics is paramount to approval, but process dependent. In this segment of the In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, Christian Dohmen, Senior Director of Formulation & Aerosol Research at Ethris, and Patrick Baumhof, SVP of Technology at CureVac address safety risks and how mRNA developers are tackling the challenges
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Roche CustomBiotech
This website uses cookies to ensure you get the best experience on our website. Learn more